Avantor vs BioMarin Pharmaceutical

Avantor (AVTR), health care, and BioMarin Pharmaceutical (BMRN), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

BioMarin Pharmaceutical is worth $11.3B on the stock market and Avantor $10.3B: BioMarin Pharmaceutical is valued at 10% more. Avantor's operating margin in its latest fiscal year was -3.76% and BioMarin Pharmaceutical's 12.7%. Over the past year Avantor's share price has moved +37.5% and BioMarin Pharmaceutical's +7.07%.

Key facts

Avantor market value
$10.3B
BioMarin Pharmaceutical market value
$11.3B
Avantor P/E
30.4
Avantor revenue
$6.6BFY to 2025-12-31
BioMarin Pharmaceutical revenue
$3.2BFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

Avantor vs BioMarin Pharmaceutical: every measure side by side
Measure Avantor BioMarin Pharmaceutical
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$10.3Blower$11.3Bhigher
Revenue$6.6Bhigher$3.2Blower
Earnings-$530.2Mlower$348.9Mhigher
Employees13,500higher3,221lower
Total assets$11.8Bhigher$7.6Blower
Valuation
P/E30.4—
P/S1.6lower3.5higher
P/B1.8lower1.8higher
Dividend yield0.00%0.00%
Profitability
Operating margin-3.76%lower12.7%higher
Balance sheet
Net assets$5.6Blower$6.1Bhigher
Total liabilities$6.2Bhigher$1.5Blower
Total debt$3.9B—
Cash on hand$365.4Mlower$1.3Bhigher
Price change
Today-0.91%lower+0.90%higher
1 year+37.5%higher+7.07%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Avantor / BioMarin Pharmaceutical). Who owns AVTR · Who owns BMRN

Further comparisons

Learn

Questions and answers

Which is bigger, Avantor or BioMarin Pharmaceutical?

By market value, BioMarin Pharmaceutical is the larger: $11.3B against $10.3B for Avantor. By revenue in its latest fiscal year, Avantor is the larger: $6.6B against $3.2B for BioMarin Pharmaceutical.

Which has the higher operating margin?

BioMarin Pharmaceutical: 12.7%, against -3.76% for Avantor. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Avantor and BioMarin Pharmaceutical?

In their latest 13F filings, Dodge & Cox team holds both.

Cite this page

Funkfolio, “Avantor vs BioMarin Pharmaceutical”, data as of 17 November 2026. https://funkfolio.com/compare/avtr-vs-bmrn

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.